CoChat

Acarbose in the treatment of elderly patients with type 2 diabetes

Josse, R.G, Chiasson, J.-L, Ryan, E.A, Lau, D.C.W, Ross, S.A, Yale, J.-F, Leiter, L.A, Maheux, P, Tessier, D, Wolever, T.M.S, Gerstein, H, Rodger, N.W, Dornan, J.M, Murphy, L.J, Rabasa-Lhoret, R, Meneilly, G.S · 2003 · Diabetes Research and Clinical Practice

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Aims To study the effect of acarbose, an alpha-glucosidase inhibitor, on glycemic control in elderly patients with type 2 diabetes.Methods Elderly patients with type 2 diabetes treated with diet alone were randomly treated in a double-blind fashion with placebo (n=99) or acarbose (n=93) for 12 months.Results After 12 months of therapy, there was a statistically significant difference in the change in glycated haemoglobin (HbA(1c)) (-0.6%) in the acarbose group versus placebo, as well as in the incremental post-prandial glucose values (-2.1 mmol h/l) and mean fasting plasma glucose (-0.7 mmol/l). Although there was no effect of acarbose on insulin release, there was a clear effect of acarbose to decrease relative insulin resistance (-0.8) (HOMA method). In addition, acarbose was generally well tolerated and safe in the elderly; most discontinuations were due to gastrointestinal side effects such as flatulence and diarrhea. There were no cases of hypoglycemia reported, and no clinically relevant changes in laboratory abnormalities or vital signs during the study.Conclusions Acarbose improves the glycemic profile and insulin sensitivity in elderly patients with type 2 diabetes who are inadequately controlled on diet alone.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0168-8227(02)00176-6

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Cited by

See all 110

Metadata

Authors
Josse, R. G., Chiasson, J.-L., Ryan, E. A., Lau, D. C. W., Ross, S. A., Yale, J.-F., Leiter, L. A., Maheux, P., Tessier, D., Wolever, T. M. S., Gerstein, H., Rodger, N. W., Dornan, J. M., Murphy, L. J., Rabasa-Lhoret, R., & Meneilly, G. S.
Affiliations
  • University of Toronto (CA)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • University of Alberta (CA)
  • University of Calgary (CA)
  • McGill University (CA)
  • Université de Sherbrooke (CA)
  • McMaster University (CA)
  • Western University (CA)
  • Saint John Regional Hospital (CA)
  • University of Manitoba (CA)
  • University of British Columbia Hospital (CA)
Venue
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Published
2003-01
Volume
59
Issue
1
Pages
37-42
ISSN
0168-8227 (ISSN-L)
OpenAlex
W2118451434
Cited by
110
References
20
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 5 · 2017: 5 · 2016: 3 · 2015: 8 · 2014: 6 · 2013: 3 · 2012: 2
FWCI
2.50
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Diabetes Research and Clinical Practice (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
acarbose, alpha-glucosidase inhibitors, type 2 diabetes, elderly patients, glycemic control, HbA1c, postprandial blood glucose, fasting blood glucose, insulin resistance, insulin secretion, gastrointestinal adverse effects, drug safety
MeSH terms
Aged, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Flatulence, Humans, Hypoglycemic Agents, Male, Treatment Outcome, Acarbose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acarbose in the treatment of elderly patients with type 2 diabetes. https://app.cochat.ai/papers/10.1016/s0168-8227(02)00176-6
The paper
Josse, R. G., Chiasson, J.-L., Ryan, E. A., Lau, D. C. W., Ross, S. A., Yale, J.-F., Leiter, L. A., Maheux, P., Tessier, D., Wolever, T. M. S., Gerstein, H., Rodger, N. W., Dornan, J. M., Murphy, L. J., Rabasa-Lhoret, R., & Meneilly, G. S. (2003). Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Research and Clinical Practice. https://doi.org/10.1016/s0168-8227(02)00176-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.